Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...

Triple-negative breast cancer is a fast-moving form of breast cancer that’s more common in younger women and harder to treat ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...

Data from the Phase Ib Beamion LUNG-1 trial evaluating HERNEXEOS® (zongertinib tablets) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant ...

Strickland survived a lesser-known, aggressive form of breast cancer, and is now using her second chance on life to be an ...

New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early ...

After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor ...

October is Breast Cancer Awareness Month Having a family history that spanned four generations of breast cancer survivors, ...

OS Therapies Incorporated ( ($OSTX) ) just unveiled an announcement. On October 17, 2025, OS Therapies Incorporated announced the posting of an ...

In my mind, if you have cancer, it’s going to feel like a marble, something hard and foreign. That’s not how this felt.” ...